
DYN
Dyne Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
9.250
Open
9.250
VWAP
--
Vol
--
Mkt Cap
1.28B
Low
9.250
Amount
--
EV/EBITDA(TTM)
--
Total Shares
99.46M
EV
698.52M
EV/OCF(TTM)
--
P/S(TTM)
--
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
--
--
-0.936
+6.39%
--
--
-0.946
-1.47%
--
--
-0.933
+33.34%
Estimates Revision
Stock Price
Go Down

-20.56%
In Past 3 Month
14 Analyst Rating

305.84% Upside
Wall Street analysts forecast DYN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DYN is 37.54 USD with a low forecast of 9.00 USD and a high forecast of 66.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
2 Hold
0 Sell
Strong Buy

305.84% Upside
Current: 9.250

Low
9.00
Averages
37.54
High
66.00

305.84% Upside
Current: 9.250

Low
9.00
Averages
37.54
High
66.00
Evercore ISI
Gavin Clark-Gartner
Outperform
downgrade
$46 -> $41
2025-07-11
Reason
Evercore ISI
Gavin Clark-Gartner
Price Target
$46 -> $41
2025-07-11
downgrade
Outperform
Reason
Evercore ISI analyst Gavin Clark-Gartner lowered the firm's price target on Dyne Therapeutics to $41 from $46 and keeps an Outperform rating on the shares. The firm adjusted price targets in Smid-cap biotechnology as part of a research note discussing 2026 stock ideas. There is a "notable lengthening" of time horizons among investors, which is a positive sign for the broader small cap biotech markets, the analyst tells investors in a research note.
JonesResearch
NULL -> Buy
initiated
$30
2025-06-25
Reason
JonesResearch
Price Target
$30
2025-06-25
initiated
NULL -> Buy
Reason
Bernstein
Bernstein
Market Perform
initiated
$13
2025-06-24
Reason
Bernstein
Bernstein
Price Target
$13
2025-06-24
initiated
Market Perform
Reason
Baird
Outperform -> NULL
downgrade
$46 -> $32
2025-06-19
Reason
Baird
Price Target
$46 -> $32
2025-06-19
downgrade
Outperform -> NULL
Reason
Baird lowered the firm's price target on Dyne Therapeutics to $32 from $46 and keeps an Outperform rating on the shares. The firm updated its model following the swapping of the DYNE-101 endpoint from splicing to vHOT.
Raymond James
Martin Auster
Outperform
initiated
$37
2025-06-10
Reason
Raymond James
Martin Auster
Price Target
$37
2025-06-10
initiated
Outperform
Reason
Raymond James analyst Martin Auster assumed coverage of Dyne Therapeutics with an Outperform rating and $37 price target as part of a broader research note on selection Biotech names. Risk/reward skews favorably across the sector, though while companies with high PoS - probability of success - lead assets allow for higher conviction, highly attractive skews on less de-risked assets may deliver the most outsized returns, the analyst tells investors in a research note. For the stock, the firm notes that while it is trading at an enterprise value below $1B, Dyne's increasingly clinically-validated FORCE platform offers a compelling long-term risk-reward with proof of concept established on two assets in valuable, high unmet need markets, Raymond James added.
Oppenheimer
Andreas Argyrides
Outperform
downgrade
$60 -> $34
2025-06-02
Reason
Oppenheimer
Andreas Argyrides
Price Target
$60 -> $34
2025-06-02
downgrade
Outperform
Reason
Oppenheimer analyst Andreas Argyrides assumed coverage of Dyne Therapeutics with an Outperform rating with a price target of $34, down from $60, after the company reported its Q1 and highlighted progress across its DM1 and Duchenne muscular dystrophy programs. In the Phase 1/2 ACHIEVE trial of DYNE-101 in DM1, following the recent compelling data, the firm is encouraged to see the registrational expansion cohort staying on track for readout in the first half of 2026. Management highlighted its recent participation in a CDER Type C held in May 2025 for DYNE-101 in DM1, and plans to provide a regulatory update following receipt of meeting minutes. In the Phase 1/2 DELIVER trial of DYNE-251 in DMD, the registrational expansion cohort readout remains expected in late 2025.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Dyne Therapeutics Inc (DYN.O) is -2.66, compared to its 5-year average forward P/E of -5.68. For a more detailed relative valuation and DCF analysis to assess Dyne Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-5.68
Current PE
-2.66
Overvalued PE
-2.30
Undervalued PE
-9.05
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-3.92
Current EV/EBITDA
-1.66
Overvalued EV/EBITDA
-0.70
Undervalued EV/EBITDA
-7.15
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
YoY :
+76.95%
-122.37M
Operating Profit
FY2025Q1
YoY :
+75.72%
-115.36M
Net Income after Tax
FY2025Q1
YoY :
+29.63%
-1.05
EPS - Diluted
FY2025Q1
YoY :
+35.75%
-106.87M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
1.9K
USD
1
3-6
Months
54.5K
USD
4
6-9
Months
4.8M
USD
10
0-12
Months
43.4M
USD
34
Bought
0-3
1
911.0K
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
1.1M
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 701.06% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
3.9M
Volume
2
6-9
Months
4.9M
Volume
7
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
6
11.4M
Volume
Months
6-9
4
1.4M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
1.9K
USD
1
3-6
Months
54.5K
USD
4
6-9
Months
4.8M
USD
10
0-12
Months
43.4M
USD
34
Bought
0-3
1
911.0K
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
1.1M
USD
Months
DYN News & Events
Events Timeline
2025-07-28 (ET)
2025-07-28
16:13:28
Dyne Therapeutics expects cash to fund operations into Q3 of 2027

2025-07-28
16:13:01
Dyne Therapeutics reports Q2 EPS (97c), consensus (93c)

2025-07-01 (ET)
2025-07-01
06:05:05
Dyne Therapeutics 24.2M share Spot Secondary priced at $8.25

Sign Up For More Events
Sign Up For More Events
News
9.5
07-28NASDAQ.COMPinnedDyne Therapeutics, Inc. Q2 Loss Increases, Misses Estimates
4.0
10:35 AMBenzingaChardan Capital Maintains Buy on Dyne Therapeutics, Lowers Price Target to $38
7.0
07-28GlobenewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
Sign Up For More News
People Also Watch

SCL
Stepan Co
56.090
USD
-1.57%

LEG
Leggett & Platt Inc
10.285
USD
-0.78%

BLX
Foreign Trade Bank of Latin America Inc
41.210
USD
-2.63%

LADR
Ladder Capital Corp
11.150
USD
-0.81%

STBA
S&T Bancorp Inc
37.680
USD
+0.03%

VRDN
Viridian Therapeutics Inc
17.400
USD
-0.12%

VBTX
Veritex Holdings Inc
32.370
USD
-1.09%

SPNS
Sapiens International Corporation NV
29.090
USD
+1.03%

ACDC
ProFrac Holding Corp
8.200
USD
+5.04%
FAQ

What is Dyne Therapeutics Inc (DYN) stock price today?
The current price of DYN is 9.25 USD — it has decreased -6.87 % in the last trading day.

What is Dyne Therapeutics Inc (DYN)'s business?

What is the price predicton of DYN Stock?

What is Dyne Therapeutics Inc (DYN)'s revenue for the last quarter?

What is Dyne Therapeutics Inc (DYN)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Dyne Therapeutics Inc (DYN)'s fundamentals?

How many employees does Dyne Therapeutics Inc (DYN). have?
